Heron Therapeutics, Inc. (HRTX)
| Market Cap | 1.60B |
| Revenue (ttm) | 103.12M |
| Net Income (ttm) | -222.92M |
| Shares Out | 90.85M |
| EPS (ttm) | -2.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $17.64 |
| Previous Close | $17.64 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 18.13 |
| Day's Range | 17.55 - 18.30 |
| Day's Volume | 980,993 |
| 52-Week Range | 10.23 - 24.53 |
SAN DIEGO, Jan. 11, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-clas...
Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
SAN DIEGO, Nov. 11, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-clas...
This biotech titan should be a top player on the merger and acquisition scene next year.
Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
It's a good time to separate the weak from the strong. The post 7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio appeared first on InvestorPlace.
Heron's (HRTX) Zynrelef gains a marketing nod from the European Commission for managing postoperative pain in surgical wounds among adult patients. Stock rises.
SAN DIEGO, Sept. 28, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-cla...
SAN DIEGO, Sept. 11, 2020 /PRNewswire/ -- Heron Therapeutics, Inc.
SAN DIEGO, Sept. 8, 2020 /PRNewswire/ -- Heron Therapeutics, Inc.
Bargain hunters pounced on this beaten-down biotech stock last month. Here's why.
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -3.39% and 38.64%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, Aug. 5, 2020 /PRNewswire/ -- Heron Therapeutics, Inc.
Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.
Heron's (HRTX) NDA seeking approval for pipeline candidate, HTX-011, for the management of postoperative pain gets CRL from the FDA, based on non-clinical issues. Shares down.
Its non-opioid painkiller gets a rejection over non-clinical issues.
Investors need to pay close attention to Heron Therapeutics (HRTX) stock based on the movements in the options market lately.
SAN DIEGO, June 29, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-clas...
Heron Therapeutics and Novavax are two key healthcare stocks to watch this month.
Heron Therapeutics (NASDAQ: HRTX) shares are trading higher on Wednesday after Guggenheim initiated coverage on the company's stock with a Buy rating and $24 price target.
AbbVie, Adverum Biotechnologies, and Heron Therapeutics could all be gearing up for a strong May. Here's why.
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 9.52% and 25.36%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics and Intercept Pharmaceuticals are too cheap to ignore right now.
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -12.07% and 0.81%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the...
Heron Therapeutics: Looking For Entry Following HTX-011 PDUFA Extension
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Heron Therapeutics is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Biotech investment is risk fraught. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts.
As of late, it has definitely been a great time to be an investor in Heron Therapeutics, Inc. (HRTX).
Heron Therapeutics: Looking Solid Heading Into 2020
Heron Therapeutics (HRTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 30.00% and 25.64%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for th...
Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These are five stocks to consider buying because of significant insider buying activity. Insiders only buy for one reason: to make money.
A high-risk transformative move sent one of these stocks lower.
The steep sell-off in biotech over the past two weeks has obscured some positive developments around Heron Therapeutics.
Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
You should never blindly follow the crowd, but it pays to watch what the biggest and brightest on Wall Street are doing.
Despite better than expected Q2 results, the stock of small biopharma Heron Therapeutics sits near 52-week lows.
The biotechnology industry is an exciting one. A mix of technology and a better understanding of the human body has led to several very exciting breakthroughs over the past several years, and ...
Amarin and Heron Therapeutics could turn out to be outstanding bargains.
Not all CRLs are created equal. Investors likely overreacted to the recent announcement of Heron’s Complete Response Letter.
These stocks are bargains.
The FDA gave Heron Therapeutics' HTX-011 drug a CRL after issues were noted with the CMC and non-clinical information portion of the application.
Heron's falling share price last month turned out to be a bad omen.
Heron is a fundamentally sound company undergoing what is seemingly a temporary share price depreciation.
About HRTX
Heron Therapeutics, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclop... [Read more...]
| Industry Biotechnology | IPO Date Aug 26, 1987 |
| CEO Barry Quart | Employees 231 |
| Stock Exchange NASDAQ | Ticker Symbol HRTX |
Financial Performance
In 2019, HRTX's revenue was $145.97 million, an increase of 88.41% compared to the previous year's $77.47 million. Losses were -$204.75 million, 14.5% more than in 2018.
Analyst Forecasts
According to 9 analysts, the average rating for HRTX stock is "Strong Buy." The 12-month stock price forecast is 32.10, which is an increase of 81.97% from the latest price.